Navigation Links
TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS' SciFinder®
Date:4/4/2011

KOLKATA, India, April 4, 2011 /PRNewswire/ -- Chemical Abstracts Service (CAS), the world's authority for chemical information, announced today that TCG Lifesciences Limited, a leading contract research services and informatics company based in India, has signed a three-year contract to provide its scientists and researchers with unlimited access to SciFinder. SciFinder will help TCG Lifesciences grow its position as a contract research organization that provides a new paradigm of cutting edge drug discovery and development platform in the competitive and fast growing Indian pharmaceutical research space.

"We have had a relationship with CAS for a long time, hence when we were required to select an enterprise-wide research platform for our R&D teams, SciFinder was the clear choice, given its reliable, high-quality content and advanced reaction planning tools. Our scientists now have on-demand access to the largest collection of small molecules and related information, including references to millions of peer-reviewed research papers and patents. SciFinder gives our researchers the insight they need to produce the flagship laboratory data for which we are known," said Dr. Sourav Basu, Associate Vice-President of TCG Lifesciences.

SciFinder, the world's leading research and discovery tool, will offer TCG Lifesciences teams a variety of powerful research and analysis options, including Markush searching for retrieving additional patents for substances that are claimed in generic terms, and the recently-announced SciPlanner™, an interactive reaction planning workspace especially valuable for pharmaceutical and biotechnology research.

SciFinder's comprehensive and current content, sophisticated analysis and collaboration capabilities, and demonstrated results inside the lab and out have made it the preferred source of chemical information for scientists around the globe. Its streamlined navigation and intuitive interface integrated with CAS' trusted content gives researchers confidence in the quality of their work.

"CAS is committed to providing the most complete collection of reliable chemical information needed by chemists and other researchers to drive innovation," said Robert J. Massie, president of CAS. "We look forward to supporting TCG Lifesciences' work in the arena of drug discovery and development, as they continue to enhance and make potential life-saving advancements through their R&D efforts."

Related links
SciFinder- Essential content. Proven results.

About SciFinder

SciFinder® is the first choice of scientists conducting research in chemistry and related fields. The award-winning application offers access to the CAS REGISTRY(SM) database, known as the gold standard of chemical substance collections. In addition, SciFinder retrieves more references than any other scientific search service, including relevant patent documents, journal article information, and reliable web sources. Finally, SciFinder is secure; its confidential research results are guaranteed and protected by CAS' secured systems.

About CAS

Chemical Abstracts Service (CAS), a division of the American Chemical Society, is the world's authority for chemical information. Our databases are curated and quality-controlled by CAS scientists, and recognized by chemical and pharmaceutical companies, universities, government organizations, and patent offices around the world as authoritative. By combining these databases with advanced search and analysis technologies (SciFinder®, STN®, and Science IP® products and services), CAS delivers the most current, complete, and cross-linked secure digital information environment for scientific discovery. Learn more at http://www.cas.org.

About TCG Lifesciences Limited
TCG Lifesciences Limited is a leading Contract Research Services, clinical research, and laboratory informatics company with operations in India, Europe, Japan, and the United States. It is part of The Chatterjee Group, a global investment conglomerate headquartered in New York. TCGLS collaborates to service the multi-disciplinary research efforts of global pharmaceutical and biotechnology companies through its three units: Chembiotek (Discovery Research), Clininvent (Clinical Research Solutions), and LabVantage (Enterprise Informatics). It has trust based relationships with a majority of the global pharmaceutical companies. The relationships span from specific solutions and sourcing services to integrated projects across multiple domains to complete translational research programs in the drug discovery and development space. Learn more at http://www.tcgls.com/.


'/>"/>
SOURCE Chemical Abstracts Service
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lifesciences IT Spending to Experience Mature Growth Rates Despite Economic Slowdown, Declares Frost & Sullivan
2. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
3. CarePoint Partners Expands Florida Footprint With Acquisition of Infusion Technologies
4. Digital Assent Expands Leadership Team to Address Rapidly Growing Demand for the PatientPad
5. Delcath Expands Board of Directors With Appointment of Gabriel Leung
6. HCPC Expands Annual Event to Drive Pharma Collaboration
7. Prognosis Health Information Systems Expands Executive Team
8. Anodizing Leader Expands Capacity at U.S. Facility
9. Transgenomic Expands COLD-PCR License
10. Dendreon Expands Launch of PROVENGE
11. Remedi SeniorCare Expands Distribution of the Paxit™ Med-Pass Solution, the New Standard in Medication Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):